MedTrace Logo

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

NCT00086866 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2015-02-10

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: This randomized phase II trial is studying two different regimens of vaccine therapy and comparing them to see how well they work in treating patients with stage III or stage IV melanoma that cannot be removed with surgery.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

D1/3-MAGE-3-His fusion protein

BIOLOGICAL

SB-AS02B adjuvant

BIOLOGICAL

SB-AS15 adjuvant

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Willem H. J. Kruit, MD, PhD · Daniel Den Hoed Cancer Center at Erasmus Medical Center

  • Cornelis J. A. Punt, MD, PhD · Universitair Medisch Centrum St. Radboud - Nijmegen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2007-01-31

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00086866 on ClinicalTrials.gov